Compare IKT & MNTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IKT | MNTK |
|---|---|---|
| Founded | 2008 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Natural Gas Distribution |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.2M | 202.0M |
| IPO Year | 2020 | 2020 |
| Metric | IKT | MNTK |
|---|---|---|
| Price | $1.67 | $1.62 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $5.00 | $1.80 |
| AVG Volume (30 Days) | ★ 673.0K | 189.1K |
| Earning Date | 03-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $176,382,000.00 |
| Revenue This Year | N/A | $18.55 |
| Revenue Next Year | N/A | $12.68 |
| P/E Ratio | ★ N/A | $146.00 |
| Revenue Growth | N/A | ★ 0.37 |
| 52 Week Low | $1.33 | $1.07 |
| 52 Week High | $2.26 | $2.78 |
| Indicator | IKT | MNTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.94 | 50.94 |
| Support Level | $1.64 | $1.59 |
| Resistance Level | $1.76 | $1.78 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 40.54 | 29.84 |
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.